Pinworm medication may treat aggressive skin cancer: Researchers

The research led by University of Arizona Cancer Center and published in the Journal of Clinical Investigation, found that in laboratory models of Merkel cell carcinoma, pyrvinium pamoate inhibited cancer cell growth and reversed the cancer’s neuroendocrine features.

In mouse models of Merkel cell carcinoma, pyrvinium pamoate reduced tumour growth.

Merkel cell carcinoma is a rare but fast-growing neuroendocrine cancer that is three to five times more likely than melanoma to be deadly. Response rates to current therapies – surgery, radiation and immunotherapy – are limited, resulting in a need for effective and broadly applicable therapeutics.

“Merkel cell carcinoma is increasing in incidence. Even though it’s a rare cancer type, it mimics a lot of properties that other cancers have,” said senior author Megha Padi, assistant professor at the university.

Pyrvinium pamoate, a medication approved by the Food and Drug Administration in 1955 to treat pinworms, has been shown to have antitumour potential in several different cancers, including breast, colorectal, pancreatic and bladder cancers. This is the first time it has been studied in models of Merkel cell carcinoma.

Padi and the research team found that in laboratory models of Merkel cell carcinoma, pyrvinium pamoate inhibited cancer cell growth and reversed the cancer’s neuroendocrine features. In mouse models of Merkel cell carcinoma, pyrvinium pamoate reduced tumor growth.

“This is a hypothesis, but some people think the reason an antiparasitic agent could be effective against cancers is because tumours are a little bit like parasites in our body,” Padi said. “Parasites and tumours must develop ways to use scarce resources in their host to feed themselves and allow for unlimited multiplication. If the pathways that they have hijacked to feed themselves are the same, then you get lucky, and you have a tumour type that could be amenable to killing by these antiparasitic drugs.”

—IANS